Study May Aid AYAs in Weighing Risks, Benefits of Clinical Trial Participation
Trends in favor of better clinical outcomes were observed for those on-trial in this retrospective matched cohort study of patients with cancer who were treated on a phase III clinical trial compared with those who received standard therapy and/or were off trial. (Source: CancerNetwork)
Source: CancerNetwork - June 9, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

Patients See Benefit with Telemedicine Visits Compared with In-Person Visits
It was suggested that telemedicine for patients in an interventional radiology group increases access to care and allows for more efficient use of physician time and resources. (Source: CancerNetwork)
Source: CancerNetwork - June 9, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

Study Supports Increased Referrals of Genetic Testing in African American Women
A recent study demonstrated the validity of current breast cancer testing panels for use in African American women and provides a basis for increased referral of this patient population for cancer genetic testing. (Source: CancerNetwork)
Source: CancerNetwork - June 9, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

Elizabeth Plimack, MD, MS, Discusses Subsequent Therapy in Advanced RCC
Elizabeth Plimack, MD, MS, discussed the role of subsequent immunotherapy when analyzing the primary endpoint of overall survival for axitinib and pembrolizumab over sunitinib in patients with advanced renal cell carcinoma evaluated in the updated analysis of KEYNOTE-426. (Source: CancerNetwork)
Source: CancerNetwork - June 9, 2020 Category: Cancer & Oncology Authors: Elizabeth R. Plimack, MD, MS Source Type: news

Belantamab Mafodotin Triplet Yields Promising Clinical Benefit in Relapsed/Refractory Multiple Myeloma
The combination use of belantamab mafodotin plus bortezomib   and dexamethasone induced high clinical benefit rates and a tolerable safety profile in patients with relapsed or refractory multiple myeloma. (Source: CancerNetwork)
Source: CancerNetwork - June 8, 2020 Category: Cancer & Oncology Authors: Lisa Astor Source Type: news

Meletios A. Dimopoulos, MD, on the Phase III BOSTON Study in Multiple Myeloma
Meletios A. Dimopoulos, MD, discussed the phase III Boston study examining a new combination therapy to treat patients with multiple myeloma who have received 1 to 3 prior therapies. (Source: CancerNetwork)
Source: CancerNetwork - June 8, 2020 Category: Cancer & Oncology Authors: Meletios A. Dimopoulos, MD Source Type: news

Constantine Si Lun Tam, MD, MBBS, FRACP, FRCPA, on Results of the Phase III ASPEN Trial
The trial compared zanubrutinib, a potent and selective BTK inhibitor, versus ibrutinib, a first generation BTK inhibitor, in patients with Waldenstr öm macroglobulinemia. (Source: CancerNetwork)
Source: CancerNetwork - June 8, 2020 Category: Cancer & Oncology Authors: Constantine Si Lun Tam, MD, MBBS, FRACP, FRCPA Source Type: news

Clinical Improvement Found After Administration of Acalabrutinib for Patients with COVID-19
A recent study, sparking further trials for investigation, saw improved clinical outcomes and reduced markers of inflammation for patients with severe COVID-19 after treatment with acalabrutinib, a selective BTK inhibitor. (Source: CancerNetwork)
Source: CancerNetwork - June 8, 2020 Category: Cancer & Oncology Authors: Matthew Fowler Source Type: news

JNJ-4528 Continues to Show Durable Responses in Relapsed/Refractory Multiple Myeloma
The CAR T-cell therapy continued to demonstrate deep and durable responses in heavily pretreated patients with relapsed/refractory multiple myeloma. (Source: CancerNetwork)
Source: CancerNetwork - June 7, 2020 Category: Cancer & Oncology Authors: Tony Berberabe, MPH Source Type: news

Caron A. Jacobson, MD, on the Interim Phase II ZUMA-5 Study Safety and Efficacy Findings
The study evaluated the use of axicabtagene ciloleucel (axi-cel) in patients with relapsed or refractory indolent non-Hodgkin lymphoma. (Source: CancerNetwork)
Source: CancerNetwork - June 7, 2020 Category: Cancer & Oncology Authors: Caron A. Jacobson, MD Source Type: news

Ide-cel Appears Active in Almost Three-Fourths of Heavily Pretreated Patients with Myeloma
The BCMA-targeting CAR T-cell therapy yielded a response in73% of patients with heavily pretreated relapsed/refractory multiple myeloma. (Source: CancerNetwork)
Source: CancerNetwork - June 6, 2020 Category: Cancer & Oncology Authors: Jason M. Broderick Source Type: news

ASCO Expert Discusses the Use of Autologous Transplantation in Relapsed DLBCL
Nirav Niranjan Shah, MD, spoke about the use of autologous stem cell transplant in patients with relapsed, chemosensitive DLBCL during the era of CAR T-cell therapy. (Source: CancerNetwork)
Source: CancerNetwork - June 6, 2020 Category: Cancer & Oncology Authors: Nirav Niranjan Shah, MD Source Type: news

Quiz: When to Use Endoscopy for Acute Upper Gastrointestinal Bleeding
In our gastrointestinal cancer quiz, you ’ll get a chance to test your knowledge on the use of endoscopy for acute upper gastrointestinal bleeding. (Source: CancerNetwork)
Source: CancerNetwork - June 5, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

Parameswaran Hari, MD, MRCP, Discusses Lenalidomide Maintenance Outcomes in Multiple Myeloma
Parameswaran Hari, MD, MRCP, discussed the progression-free survival of patients who stopped versus continued lenalidomide maintenance therapy to treat multiple myeloma from a follow-up trial presented at the 2020 ASCO Virtual Scientific Program. (Source: CancerNetwork)
Source: CancerNetwork - June 5, 2020 Category: Cancer & Oncology Authors: Parameswaran Hari, MD, MRCP Source Type: news

CC-92480 Plus Dexamethasone Shows Favorable Activity in Relapsed/Refractory Myeloma
CC-92480 in combination with dexamethasone demonstrated favorable activity and safety data in patients with heavily pretreated relapsed or refractory multiple myeloma. (Source: CancerNetwork)
Source: CancerNetwork - June 5, 2020 Category: Cancer & Oncology Authors: Dylann Cohn-Emery Source Type: news

Niraparib-Bevacizumab Combo Improves Clinical Outcomes in Recurrent Ovarian Cancer
The combination use of niraparib plus bevacizumab significantly improved clinical outcomes, compared with niraparib alone, in patients with recurrent ovarian cancer. (Source: CancerNetwork)
Source: CancerNetwork - June 5, 2020 Category: Cancer & Oncology Authors: Audrey Sternberg Source Type: news

Michael J. Morris, MD on the Impact of PyL-PET/CT Scans on the Clinical Management of Patients With Prostate Cancer
An analysis of the secondary endpoint of the phase III CONDOR study showed PSMA scans had a profound impact on patient care. (Source: CancerNetwork)
Source: CancerNetwork - June 4, 2020 Category: Cancer & Oncology Authors: Michael J. Morris, MD Source Type: news

Tucatinib Combination Induces Positive Intracranial Responses in HER2-Positive Breast Cancer Brain Metastases
Tucatinib in combination with trastuzumab and capecitabine yielded significant intracranial responses in patients with previously treated HER2-positive metastatic breast cancer and brain metastases. (Source: CancerNetwork)
Source: CancerNetwork - June 4, 2020 Category: Cancer & Oncology Authors: Lisa Astor Source Type: news

Neal D. Shore, MD, FACS Discusses Impact, Treatment Implications of the Phase III HERO Trial
The Carolina Urologic Research Center expert discusses the benefits of oral relugolix for patients with prostate cancer. (Source: CancerNetwork)
Source: CancerNetwork - June 4, 2020 Category: Cancer & Oncology Authors: Neal D. Shore, MD, FACS Source Type: news

Andres Poveda, MD, on the Phase III SOLO2/ENGOT-ov21 Final OS Data in Ovarian Cancer
Final overall survival results from the trial showed that maintenance olaparib provided an unprecedented improvement in median overall survival versus placebo in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA mutation. (Source: CancerNetwork)
Source: CancerNetwork - June 4, 2020 Category: Cancer & Oncology Authors: Andres Poveda, MD Source Type: news

Zsofia K. Stadler, MD, on the Importance of Germline Analyses in Advanced Cancer
Germline analysis in patients with advanced cancer may play an important role in selecting FDA-approved treatments and clinical trial participation with germline-targeted therapeutics. (Source: CancerNetwork)
Source: CancerNetwork - June 3, 2020 Category: Cancer & Oncology Authors: Zsofia K. Stadler, MD Source Type: news

Thomas Powles, MD, PhD on Next Steps for Avelumab and the Future of Treatment for Urothelial Cancer
The expert from Barts Cancer Centre in London discusses future directions for avelumab and the rapidly advancing field of urothelial cancer. (Source: CancerNetwork)
Source: CancerNetwork - June 3, 2020 Category: Cancer & Oncology Authors: Thomas Powles, MD, PhD Source Type: news

Belantamab Mafodotin Shows Promising Response in Relapsed/Refractory Multiple Myeloma
Belantamab mafodotin monotherapy induced durable responses and appeared to be well tolerated   in patients with heavily pretreated relapsed or refractory multiple myeloma. (Source: CancerNetwork)
Source: CancerNetwork - June 3, 2020 Category: Cancer & Oncology Authors: Brittany Lovely Source Type: news

Roy S. Herbst, MD, PhD, Talks Key Takeaway from Phase III ADAURA Trial
Roy S. Herbst, MD, PhD, of the Yale Cancer Center discussed his key takeaway from the phase III ADAURA trial regarding osimertinib as adjuvant therapy to treat NSCLC presented at the 2020 ASCO Virtual Scientific Program. (Source: CancerNetwork)
Source: CancerNetwork - June 3, 2020 Category: Cancer & Oncology Authors: Roy S. Herbst, MD, PhD Source Type: news

Eric Jonasch, MD, on Next Steps in MK-6482 in VHL Disease –Associated RCC
The MD Anderson Cancer Center expert discussed next steps for those with von Hippel-Lindau disease –associated renal cell carcinoma being treated with the HIF-2a Inhibitor. (Source: CancerNetwork)
Source: CancerNetwork - June 2, 2020 Category: Cancer & Oncology Authors: Eric Jonasch, MD Source Type: news

Rana R. McKay, MD, on the Impact of the Phase II OMNIVORE Trial
The expert from the University of California San Diego discusses the importance of the findings presented at the 2020 ASCO Virtual Scientific Program (Source: CancerNetwork)
Source: CancerNetwork - June 2, 2020 Category: Cancer & Oncology Authors: Rana R. Mckay, MD Source Type: news

ASCO Expert Discusses Clinical Benefit of Combination for Relapsed/Refractory Multiple Myeloma
Ajay K. Nooka, MD, MPH, FACP discussed the clinical benefits of belantamab mafodotin in combination with bortezomib/dexamethasone to treat multiple myeloma. (Source: CancerNetwork)
Source: CancerNetwork - June 2, 2020 Category: Cancer & Oncology Authors: Ajay K. Nooka, MD Source Type: news

John Kuruvilla, MD, on the Implications of the Phase III KEYNOTE-204 Study
Results from the study indicated that pembrolizumab (Keytruda) was superior to brentuximab vedotin (Adcetris) in patients with relapsed or refractory classic Hodgkin lymphoma (R/R cHL). (Source: CancerNetwork)
Source: CancerNetwork - June 2, 2020 Category: Cancer & Oncology Authors: John Kuruvilla, MD Source Type: news

Clinical Implications from the TAILORx Trial
Jane L. Meisel, MD, discusses the clinical implications of the TAILORx trial and how it has affected practice. (Source: CancerNetwork)
Source: CancerNetwork - June 1, 2020 Category: Cancer & Oncology Authors: Kristie L. Kahl Source Type: news

Matthew Steven Davids, MD, MMSc, on Venetoclax Plus R-EPOCH to Treat Richter ’s Syndrome
The CLL expert discussed the possibility of venetoclax plus dose-adjusted R-EPOCH becoming a new treatment approach in patients with CLL who developed Richter ’s Syndrome. (Source: CancerNetwork)
Source: CancerNetwork - June 1, 2020 Category: Cancer & Oncology Authors: Matthew Steven Davids, MD, MMSc Source Type: news

Thierry Andr é, MD, on Interim Results from the Phase III Keynote-177 Study
The findings, presented at the 2020 ASCO Virtual Scientific Program, are the first to show benefit with pembrolizumab in patients with advanced colorectal cancer when used as a front-line therapy. (Source: CancerNetwork)
Source: CancerNetwork - June 1, 2020 Category: Cancer & Oncology Authors: Thierry Andr é, MD Source Type: news

Benoit You, MD, PhD, on the use of Avelumab to Treat Patients With Gestational Trophoblastic Tumors
The expert from the Centre Hospitalier Lyon-Sud discussed the results of a phase II study of avelumab for patients with GTT who were resistant to chemotherapy. (Source: CancerNetwork)
Source: CancerNetwork - June 1, 2020 Category: Cancer & Oncology Authors: Benoit You, MD, PhD Source Type: news

AMG 330 Appears Safe, Tolerable in Relapsed/Refractory Acute Myeloid Leukemia
The most common, expected, and reversible treatment-emergent adverse event associated with the agent was cytokine release syndrome. (Source: CancerNetwork)
Source: CancerNetwork - May 31, 2020 Category: Cancer & Oncology Authors: Kristie L. Kahl Source Type: news

Kelly Morgan, MS, CGC, on Exploring Targeted Testing for the Ashkenazi Jewish BRCA Mutation
The MSK expert discussed the need for targeted testing for the Ashkenazi Jewish BRCA mutations in the US healthcare system. (Source: CancerNetwork)
Source: CancerNetwork - May 31, 2020 Category: Cancer & Oncology Authors: Kelly Morgan, MS, CGC Source Type: news

Addition of Cediranib to Olaparib Fails to Induce Superior PFS in Platinum-Censitive Ovarian Cancer
A phase III study using cediranib and olaparib to treat recurrent platinum-sensitive ovarian cancer did not meet its primary endpoint of progression-free survival but did produce comparable activity to standard of care platinum-based chemotherapy treatment. (Source: CancerNetwork)
Source: CancerNetwork - May 31, 2020 Category: Cancer & Oncology Authors: Matthew Fowler Source Type: news

Frontline Nivolumab/Ipilimumab with Limited Chemo Derives OS Benefit in NSCLC
Overall survival (OS) benefit derived from frontline treatment with nivolumab plus ipilimumab combined with 2 cycles of platinum-doublet chemotherapy in patients with metastatic or recurrent non-small cell lung cancer was further improved after at least 12 months of follow-up. (Source: CancerNetwork)
Source: CancerNetwork - May 31, 2020 Category: Cancer & Oncology Authors: Kristie L. Kahl Source Type: news

Interim Phase II ZUMA-5 Results Show Promise for Axi-Cel in R/R iNHL
Results showed that axicabtagene ciloleucel demonstrated significant and durable clinical benefit in patients with relapsed or refractory indolent non-Hodgkin lymphoma. (Source: CancerNetwork)
Source: CancerNetwork - May 31, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

Apalutimide Plus ADT Improves Survival in Nonmetastatic Castration-Resistant Prostate Cancer
Final data analysis of SPARTAN trial demonstrates large benefit in overall survival when compared with ADT plus placebo. (Source: CancerNetwork)
Source: CancerNetwork - May 31, 2020 Category: Cancer & Oncology Authors: Kevin Wright Source Type: news

KTE-X19 Proves Comparable to Current Therapies in Treating High-Risk MCL
When compared to currently approved therapies, KTE-X19 demonstrated comparable pharmacologic and clinical outcomes in patients with high-risk MCL characteristics versus lower-risk characteristics defined by tumor protein TP53 mutation or high Ki-67 proliferation index. (Source: CancerNetwork)
Source: CancerNetwork - May 31, 2020 Category: Cancer & Oncology Authors: Ryan McDonald Source Type: news

Courtney DiNardo, MD, on Need for Improved, Effective Regimens in IDH1-Positive AML
The MD Anderson Cancer Center expert discussed why there is an unmet need for more treatments in patients with IDH1-mutated acute myeloid leukemia. (Source: CancerNetwork)
Source: CancerNetwork - May 31, 2020 Category: Cancer & Oncology Authors: Courtney DiNardo, MD Source Type: news

Nivolumab/Ipilimumab Combo Yields Durable Efficacy in Advanced NSCLC
Frontline treatment with nivolumab plus ipilimumab induced durable and long-term efficacy, compared with chemotherapy, in patients with advanced non-small cell lung cancer, regardless of PD-L1 expression. (Source: CancerNetwork)
Source: CancerNetwork - May 30, 2020 Category: Cancer & Oncology Authors: Kristie L. Kahl Source Type: news

Phase III HERO Trial Finds Relugolix to be Superior to Leuprolide in Prostate Cancer
The results suggested the potential for this agent to become a new standard for T-suppression in this patient population. (Source: CancerNetwork)
Source: CancerNetwork - May 30, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

Pembrolizumab Shows Superior PFS in Relapsed/Refractory Classical Hodgkin Lymphoma
Results of KEYNOTE-204 supports pembrolizumab as new standard of care for patients with classical Hodgkin Lymphoma who have relapsed after autologous stem cell transplant or are ineligible for autologous stem cell transplant. (Source: CancerNetwork)
Source: CancerNetwork - May 30, 2020 Category: Cancer & Oncology Authors: Kevin Wright Source Type: news

Off-the-Shelf CAR T-Cell Therapy Shows Promise in Relapsed/Refractory B-Cell Lymphomas
The allogeneic CAR-T cell therapy ALLO-501, paired with the monoclonal antibody ALLO-647, demonstrated clinical responses and manageable toxicity in patients with pretreated large B-cell and follicular lymphomas in the Phase I ALPHA trial. (Source: CancerNetwork)
Source: CancerNetwork - May 30, 2020 Category: Cancer & Oncology Authors: Conor Killmurray Source Type: news

Mirvetuximab Soravtansine Combination Yields Encouraging Response Rates in Ovarian Cancer
A study presented at the 2020 ASCO Scientific Program combining mirvetuximab soravtansine with bevacizumab to treat platinum-agnostic ovarian cancer demonstrated an encouraging overall response rate and tolerability profile regardless of platinum status. (Source: CancerNetwork)
Source: CancerNetwork - May 30, 2020 Category: Cancer & Oncology Authors: Matthew Fowler Source Type: news

Amir Goldkorn, MD Discusses Baseline CTC Count as a Prognostic Marker of PSA Response and Progression in mCSPC
Baseline CTC counts were shown to be strong indicators for subsequent therapy response and 2-year progression-free survival. (Source: CancerNetwork)
Source: CancerNetwork - May 30, 2020 Category: Cancer & Oncology Authors: Amir Goldkorn, MD Source Type: news

Karen H. Lu, MD, on Addresses Gap in Genetic Counseling for Women at Risk for Ovarian Cancer
The MD Anderson Cancer Center expert spoke about the disconnect in women who are at risk for ovarian cancer to actually receive genetic counseling. (Source: CancerNetwork)
Source: CancerNetwork - May 30, 2020 Category: Cancer & Oncology Authors: undefined Source Type: news

FDA Approves Ramucirumab Injection in Combination with Erlotinib for NSCLC
The FDA approved ramucirumab injection in combination with erlotinib for the first-line treatment of patients with metastatic non-small cell lung cancer with EGFR exon 19 deletions or exon 21 mutations. (Source: CancerNetwork)
Source: CancerNetwork - May 30, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

Teclistamab Shows Promise for Patients with Relapsed/Refractory Myeloma
Teclistamab appeared to be a safe and efficacious treatment for patients with relapsed/refractory multiple myeloma, according to a phase I study presented at the ASCO Virtual Scientific Program. (Source: CancerNetwork)
Source: CancerNetwork - May 30, 2020 Category: Cancer & Oncology Authors: Brielle Benyon Source Type: news

Eric Jonasch, MD, Discusses Use of MK-6482 in VHL Disease –Associated Kidney Cancer
The HIF-2a Inhibitor, MK-6482, induced clinical responses among patients with von Hippel-Lindau disease –associated renal cell carcinoma. (Source: CancerNetwork)
Source: CancerNetwork - May 30, 2020 Category: Cancer & Oncology Authors: Eric Jonasch, MD Source Type: news